Abstract 575P
Background
Preoperative chemoradiotherapy (CRT) may enhance antitumor immunity by increasing T-cell activation and tumor infiltration. These effects could possibly sensitize tumour cells to immunecheckpoint inhibitors and other immunotherapies. We investigated the immunologic alterations occurring after preoperative CRT for locally advanced rectal cancer (LARC).
Methods
The multicenter randomized STAR-01 study compared the preoperative CRT regimen with 50.4 Gy in 28 daily fractions with concomitant infused fluorouracil at the dose of 225 mg/m2/d with the same regimen plus oxaliplatin given weekly at the dose of 60 mg/m2 in patients with LARC. Pre- and/or postoperative specimens were available for 305 patients from this trial (109 paired pre- and post-treatment samples). The immunoistochemical evaluation was performed with a panel of immune cells and associated factors such as CD3, CD20, CD4/CD8, PD-1. The pattern of tumor infiltrating lymphocytes (TILs) and related infiltrating lymphocytes (RILs) were also assessed. Microsatellite instability (MSI)/mismatch repair deficiency (dMMR) was evaluated on pre-treatment tumour biopsies.
Results
After therapy we observed a decreased CD4/CD8 ratio (P<.0001) and reduced expression levels of CD20 (P<.0001). The expression level of CD3+ and PD-1+ cells after therapy did not change significantly. The relative increase of lymphocytes CD8+ within the CD4/CD8 ratio evaluated on post-operative samples was significantly associated with pathological complete response after CRT (P<.0001), event-free survival (EFS) [hazard ratio (HR)=1.77, 95% confidence interval (CI)=1.08 to 2.89, P=.0227] and overall survival (OS) [HR=2.01, 95% CI=1.19 to 3.4, P=.0087] adjusted for treatment arm and adjuvant chemotherapy.
Conclusions
Our data indicate that CRT may induce an enrichment of CD8+ T lymphocytes and this translates in a better response to CRT and survival. Data on MSI status will be presented at the meeting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Hospital of Parma.
Funding
SNUPI onlus.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
570P - Subclasses of microsatellite-instability colorectal cancer with unique molecular features and immune cell infiltration patterns
Presenter: Kui Wu
Session: Poster session 10
571P - Artificial intelligence-powered analysis of tumor lymphocytes infiltration: A translational analysis of AtezoTRIBE trial
Presenter: Martina Carullo
Session: Poster session 10
572P - Neoantigen heterogeneity among subtypes in colorectal cancer
Presenter: Fuqiang Li
Session: Poster session 10
574P - Comparative analysis of the tumor immune microenvironment (TIME) in primary and metastatic sites of microsatellite stable (MSS) and microsatellite instability-high (MSI) colorectal cancer
Presenter: Marwan Fakih
Session: Poster session 10
576P - Prognostic values of a modified diagnostic biopsy-adapted immunoscore based on double immunohistochemical staining in patients with locally advanced rectal cancer
Presenter: Qiang Zeng
Session: Poster session 10
577P - Systematically assessing the intratissue microbiota in 937 patients with colorectal cancer
Presenter: Huanzi Zhong
Session: Poster session 10
578P - Tissue-resident microbiota characterization in colorectal cancer metastases
Presenter: Philippe Stevens
Session: Poster session 10
579P - A clinico-imaging predictive artificial intelligence model of relapse in colon cancer using baseline CT scans
Presenter: América Bueno Gómez
Session: Poster session 10
580P - Prognosis in stage II colorectal cancer: The effect of the primary tumor location and biomarkers
Presenter: Vincent Liégeois
Session: Poster session 10